Who are Pregabalin and dexmedetomidine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pregabalin-and-dexmedetomidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Pregabalin and dexmedetomidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pregabalin and dexmedetomidine (Pregabalin and dexmedetomidine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination analgesic/sedative (gabapentinoid + alpha-2 agonist). Area: Anesthesia, Pain Management, Perioperative Medicine.

marketed Combination analgesic/sedative (gabapentinoid + alpha-2 agonist) Alpha-2-delta calcium channel subunit (pregabalin); alpha-2 adrenergic receptor (dexmedetomidine) Anesthesia, Pain Management, Perioperative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Pregabalin and dexmedetomidine (Pregabalin and dexmedetomidine) — Wonkwang University Hospital. Pregabalin and dexmedetomidine together enhance pain relief and sedation by increasing inhibitory neurotransmission and activating alpha-2 adrenergic receptors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pregabalin and dexmedetomidine TARGET	Pregabalin and dexmedetomidine	Wonkwang University Hospital	marketed	Combination analgesic/sedative (gabapentinoid + alpha-2 agonist)	Alpha-2-delta calcium channel subunit (pregabalin); alpha-2 adrenergic receptor (dexmedetomidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination analgesic/sedative (gabapentinoid + alpha-2 agonist) class)

Wonkwang University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pregabalin and dexmedetomidine — Competitive Intelligence Brief. https://druglandscape.com/ci/pregabalin-and-dexmedetomidine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab